微转移在非小细胞肺癌的预后价值

The Prognostic Value of Micrometastasis in Non-small Cell Lung Cancer

肺癌是我国目前发病率和死亡率最高的恶性肿瘤。非小细胞肺癌(non-small cell lung cancer,NSCLC)占肺癌的80%-85%。诊断时的分期是NSCLC主要的预后因子,也是治疗模式选择的重要依据。然而,完全性切除术后的I期的NSCLC仍有25%-30%的复发率。这部分复发的患者可能早期就存在局部和(或)远处的隐匿性转移。因此,很多研究开始对NSCLC患者进行微转移的检测,并评估其预后价值。本文总结了近年来的相关研究,并就NSCLC的淋巴结微转移、骨髓微转移、胸膜腔微转移及外周血微转移的预后作用进行综述。

LungcancerrankstopinmorbidityandmortalityamongthemalignanciesinChina.Non-smallcelllung cancer（NSCLC） accounts for about 80%-85% of all lung malignancies.The stage at diagnosis is the principal prognostic indicator,and accurate staging is essential for treatment decisions.After radical surgical resection in patients with stage I disease,the recurrence rate ranges from 25% to 30%.Patients with a poor outcome may have occult locoregional and/or distant metastasis before resection.In recent years,there are a lot of researches aimingat detecting micrometastasis and evaluating the prognostic value of it.This study reviewed the prognostic value of micrometastasis in lymph node,bone marrow,pleural cavity and peripheral blood.